Long intergenic non-protein coding RNA 691 (LINC00691)

Long intergenic non-protein coding RNA 691 (LINC00691) is a long noncoding RNA (lncRNA) that does not encode a protein and is classified among the intergenic lncRNAs, which are located between protein-coding genes in the genome[3]. LINC00691 has been shown to be upregulated in multiple cancers, including non-small cell lung cancer and gastric cancer, where its high expression correlates with advanced tumor stage, lymph node metastasis, and poor prognosis[1][2][4]. In gastric cancer, exosomal LINC00691 acts as a circulating biomarker in serum, linked to tumor burden and disease progression[2]. Functionally, LINC00691 influences biological processes such as cell proliferation, migration, and fibroblast activation—especially promoting tumor microenvironment remodeling via pathways like JAK2/STAT3[2]. At present, there are no drugs specifically targeting LINC00691, nor is it considered a "classic" therapeutic target (such as a receptor or enzyme); rather, it is recognized as a biomarker and a potential future therapeutic target.

Other names

LINC00691long noncoding RNA LINC00691